Gemcitabine Hydrochloride Patent Expiration
Gemcitabine Hydrochloride was first introduced by Eli Lilly And Co
Gemcitabine Hydrochloride Patents
Given below is the list of patents protecting Gemcitabine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inlexzo | US12636300 | Methods Of Treatment And Maintenance Therapy For Bladder Cancer Using Gemcitabine | Nov 07, 2038 | Janssen Biotech |
| Inlexzo | US10729823 | Multi-Unit Drug Delivery Devices And Methods | Aug 19, 2034 | Janssen Biotech |
| Inlexzo | US12447241 | Multi-Unit Drug Delivery Devices And Methods | Aug 19, 2034 | Janssen Biotech |
| Infugem | US9241948 | Ready to be infused gemcetabine solution | Jul 01, 2033 | Sun Pharm |
| Inlexzo | US8679094 | Implantable Device With Intravesical Tolerability And Methods Of Treatment | Apr 15, 2032 | Janssen Biotech |
| Inlexzo | US12576253 | Drug Delivery Device With Intravesical Tolerability | Dec 17, 2030 | Janssen Biotech |
| Inlexzo | US12403086 | Solid Drug Tablets For Implantable Drug Delivery Devices | Jun 28, 2030 | Janssen Biotech |
| Gemzar |
US5464826 (Pediatric) | Method of treating tumors in mammals with 2',2'-difluoronucleosides |
May 07, 2013
(Expired) | Lilly |
| Gemzar | US5464826 | Method of treating tumors in mammals with 2',2'-difluoronucleosides |
Nov 07, 2012
(Expired) | Lilly |
Gemcitabine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gemcitabine Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
